Drug details

Zolgensma (onasemnogene abeparvovec-xioi suspension for iv use)

type of Neurologics, Other

Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• easy bruising,
• yellowing of the skin or eyes (jaundice),
• unusual bleeding, and
• purple or red spots under your skin

The following drugs are related to Zolgensma, either as a replacement or used together:

• Evrysdi (risdiplam for oral solution)